Perspective Therapeutics, Inc. (CATX)
XASE:CATX
Want to see CATX full AI Analyst Report?
Top Page
Perspective Therapeutics
(NYSE MKT:CATX)
Select Model
Select Model
Rating:48Neutral
Price Target:
$4.00
▼(-4.76% Downside)
Action:Reiterated
Date:05/14/26
The score is primarily held back by very weak financial performance (large losses and heavy cash burn) and bearish-to-soft technicals. These are partially offset by a strong, low-debt balance sheet and positive corporate developments, including encouraging interim clinical readouts and extended cash runway following financing.
Positive Factors
Conservative balance sheet / low leverage
Very low debt and sizable equity provide durable financial flexibility for multi-year clinical programs and manufacturing build-out. This lowers near-term insolvency risk, allows sustained R&D spending without immediate refinancing, and supports execution through pivotal milestones.
Negative Factors
Large cash burn
Sustained negative operating and free cash flows mean the company must continue funding operations externally. Persistent cash burn limits runway without new financing, constrains simultaneous program advancement, and raises execution risk if capital markets tighten.
Read all positive and negative factors
Positive Factors
Negative Factors
Conservative balance sheet / low leverage
Very low debt and sizable equity provide durable financial flexibility for multi-year clinical programs and manufacturing build-out. This lowers near-term insolvency risk, allows sustained R&D spending without immediate refinancing, and supports execution through pivotal milestones.
Read all positive factors
Perspective Therapeutics (CATX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$429.95M
Dividend YieldN/A
Average Volume (3M)1.36M
Price to Earnings (P/E)―
Beta (1Y)1.47
Revenue Growth-57.99%
EPS Growth-15.44%
CountryUS
Employees138
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)-1.41
Shares Outstanding114,046,196
10 Day Avg. Volume1,332,531
30 Day Avg. Volume1,355,451
Financial Highlights & Ratios
PEG Ratio-0.14
Price to Book (P/B)0.98
Price to Sales (P/S)0.00
P/FCF Ratio-2.13
Enterprise Value/Market Cap0.56
Enterprise Value/Revenue417.19
Enterprise Value/Gross Profit-116.50
Enterprise Value/Ebitda-2.17
Forecast
1Y Price Target
$12.82Price Target Upside205.19% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering13
EPS Forecast (FY)-1.12
Revenue Forecast (FY)$484.67K
Perspective Therapeutics Business Overview & Revenue Model
Company Description
Perspective Therapeutics, Inc., together with its subsidiaries, develops, manufactures, sells, and markets isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States and internationally...
How the Company Makes Money
Perspective Therapeutics primarily aims to generate future revenue through the development and commercialization (or partnering/licensing) of its radiopharmaceutical oncology candidates; however, because it is clinical-stage, recurring commercial ...
Perspective Therapeutics Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
78
Positive
Cash Flow
20
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 575.00K | 0.00 | 0.00 | 1.43M | 7.10M | 10.79M |
| Gross Profit | -2.06M | 0.00 | 0.00 | 1.43M | 1.63M | 4.62M |
| EBITDA | -110.64M | -100.80M | 10.46M | -39.96M | -14.84M | -7.39M |
| Net Income | -111.13M | -103.12M | -79.28M | -46.51M | -14.67M | -7.15M |
Balance Sheet | ||||||
| Total Assets | 410.77M | 266.97M | 341.10M | 97.89M | 58.09M | 67.25M |
| Cash, Cash Equivalents and Short-Term Investments | 270.93M | 144.74M | 226.92M | 9.24M | 43.76M | 60.35M |
| Total Debt | 2.62M | 1.63M | 4.06M | 2.55M | 0.00 | 652.00K |
| Total Liabilities | 63.33M | 59.94M | 50.43M | 22.71M | 3.45M | 2.86M |
| Stockholders Equity | 347.44M | 207.03M | 290.67M | 75.18M | 54.64M | 64.39M |
Cash Flow | ||||||
| Free Cash Flow | -107.32M | -95.23M | -72.71M | -37.98M | -12.47M | -7.98M |
| Operating Cash Flow | -92.37M | -82.48M | -18.29M | -36.91M | -12.17M | -7.71M |
| Investing Cash Flow | -62.76M | 41.23M | -218.93M | 24.37M | -57.68M | -284.00K |
| Financing Cash Flow | 164.70M | 10.30M | 289.38M | 785.00K | 56.00K | 56.00K |
Perspective Therapeutics Technical Analysis
Negative
4.20
Price Trends
4.26
Negative
4.13
Negative
3.62
Positive
Market Momentum
-0.16
Negative
43.26
Neutral
27.41
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CATX, the sentiment is Negative. The current price of 4.2 is above the 20-day moving average (MA) of 3.90, below the 50-day MA of 4.26, and above the 200-day MA of 3.62, indicating a neutral trend. The MACD of -0.16 indicates Negative momentum. The RSI at 43.26 is Neutral, neither overbought nor oversold. The STOCH value of 27.41 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CATX.
Perspective Therapeutics Risk Analysis
Perspective Therapeutics disclosed 56 risk factors in its most recent earnings report. Perspective Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Perspective Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
82 Outperform | $312.49M | 16.00 | 22.14% | ― | 16.79% | 45.17% | |
72 Outperform | $371.10M | 34.27 | 10.66% | ― | 23.10% | 22.75% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | $429.95M | -4.12 | -41.84% | ― | -57.99% | -15.44% | |
47 Neutral | $118.71M | -2.36 | -35.17% | ― | 6.85% | -90.71% | |
47 Neutral | $125.96M | -1.41 | -47.09% | ― | 15.40% | -25.87% | |
45 Neutral | $198.99M | 33.49 | 162.57% | ― | 39.64% | -25.99% |
* Healthcare Sector Average
CATX
Perspective Therapeutics
3.77
1.26
50.20%
ELMD
Electromed
37.74
17.39
85.45%
QTRX
Quanterix
2.52
-2.31
-47.83%
VMD
Viemed Healthcare
9.68
3.16
48.47%
NNOX
Nano-X Imaging
1.81
-3.43
-65.46%
TLSI
TriSalus Life Sciences
3.24
-2.11
-39.44%
Perspective Therapeutics Corporate Events
Business Operations and StrategyFinancial DisclosuresPrivate Placements and Financing
Perspective Therapeutics Highlights Q1 Progress and Strengthened Finances
Positive
May 11, 2026
Perspective Therapeutics reported first-quarter 2026 results on May 11, 2026, highlighting progress across three clinical-stage oncology programs—VMT-α-NET for neuroendocrine tumors, VMT01 for melanoma and PSV359 for FAP-positive solid ...
Business Operations and Strategy
Perspective Therapeutics Highlights Alpha-Targeted Oncology Strategy Update
Positive
May 4, 2026
On May 4, 2026, Perspective Therapeutics posted a new corporate presentation outlining its strategy to engineer an “alpha advantage” in targeted oncology using 212Pb-based radiopharmaceuticals. The materials highlight the company’...
Business Operations and StrategyProduct-Related Announcements
Perspective Therapeutics Highlights Encouraging Interim Neuroendocrine Tumor Data
Positive
Apr 20, 2026
On April 18, 2026, Perspective Therapeutics posted interim data from its ongoing Phase 1/2a trial of [212Pb]VMT-α-NET in patients with unresectable or metastatic SSTR2-positive neuroendocrine tumors, alongside an updated corporate presentatio...
Business Operations and StrategyProduct-Related Announcements
Perspective Therapeutics Highlights Progress in 212Pb Oncology Pipeline
Positive
Apr 1, 2026
On April 1, 2026, Perspective Therapeutics updated its corporate presentation to highlight progress across its wholly owned 212Pb-based oncology portfolio, emphasizing its strategy to redefine radiotherapy in solid tumors. The company underscored ...
Business Operations and StrategyFinancial DisclosuresPrivate Placements and Financing
Perspective Therapeutics Reports 2025 Results, Highlights Pipeline Progress
Positive
Mar 16, 2026
On March 16, 2026, Perspective Therapeutics reported full-year 2025 results and recent business highlights, underscoring progress across all three clinical-stage radiopharmaceutical programs and strengthening its financial position. Updated data f...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.